Canterbury DHB

Context

Diagnostic Criteria

Due to increasing evidence about the differences in outcome based on timing of diagnosis, the 2016 WHO classification of haematopietic malignancies emphasizes the differences between pre-fibrotic/early phase PMF (median survival >15 years) and overt phase PMF (median survival 3–7 years), see Rumi E, et al. (2017),1 table 2, page 3.

A bone marrow biopsy is important in this classification, especially in distinguishing between PMF and ET. A condition similar to PMF can develop in patients with pre-existing PV or ET (see Polycythaemia Vera and Essential Thrombocythaemia). Exclude secondary causes before diagnosing primary myelofibrosis.

About this Canterbury DHB document (6242):

Document Owner:

Sean Macpherson (see Who's Who)

Issue Date:

August 2018

Next Review:

April 2021

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 6242